FDA Panel Backs RSV Antibody for Infant Protection
TL;DR Summary
An FDA advisory panel has recommended the approval of a monoclonal antibody shot called Beyfortus, developed by Sanofi and AstraZeneca, to prevent respiratory syncytial virus (RSV) in infants and vulnerable toddlers. RSV is a leading killer of infants and toddlers globally, with up to 80,000 children younger than 5 hospitalized annually in the United States and up to 300 dying. The shot's safety will be monitored, and if approved, it will likely become available in the fall. The CDC is expected to advise health providers on the use of the new treatments later this month.
- F.D.A. Panel Recommends R.S.V. Shot to Protect Infants The New York Times
- FDA panel recommends drug to prevent RSV in infants NBC News
- RSV antibody drug gets backing from FDA advisors, paving the way for approval : Shots - Health News NPR
- Sanofi, AstraZeneca's RSV antibody for infants easily clears FDA adcomm, likely setting up approval FiercePharma
- FDA Panel Endorses mAb to Prevent RSV in Infants Medpage Today
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
11
Time Saved
2 min
vs 3 min read
Condensed
82%
539 → 95 words
Want the full story? Read the original article
Read on The New York Times